Straits Times Index
3,296.89 +4.20 (+0.13%) S&P 500
5,025.12 +6.73 (+0.13%) Dow
37,996.59 +93.30 (+0.25%) Nasdaq
15,662.69 +57.20 (+0.37%) Bitcoin USD
59,223.00 +1,855.43 (+3.23%) CMC Crypto 200
1,264.97 -5.77 (-0.45%)
Spero Therapeutics, Inc. (SPRO)
| Previous close | 1.5450 |
| Open | 1.5300 |
| Bid | 1.5600 x 400 |
| Ask | 1.6100 x 400 |
| Day's range | 1.5300 - 1.6400 |
| 52-week range | 0.9900 - 1.9950 |
| Volume | |
| Avg. volume | 319,362 |
| Market cap | 85.151M |
| Beta (5Y monthly) | 0.57 |
| PE ratio (TTM) | 3.67 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that on April 29, 2024, the Compensation Committee of Spero’s Board of Directors approved the grant of an aggregate of 10,833 restricted stock unit awards (RSUs) to a new employee under the Spero Therapeutics,
- GlobeNewswire
Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update
On track for topline data from SPR720 Phase 2a proof-of-concept trial in treatment-naive and treatment-experienced non-refractory NTM-PD patients, expected in 2H 2024Initiated enrollment in PIVOT-PO, a pivotal Phase 3 clinical trial of oral Tebipenem HBr in cUTI Submitted IND for SPR206 and received FDA clearance to proceed with Phase 2 clinical trialReiterate expected cash runway into late 2025Conference call and webcast at 4:30pm ET today CAMBRIDGE, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Sp
- GlobeNewswire
Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024
CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will host a conference call and live audio webcast on Wednesday, March 13, 2024 at 4:30 p.m. ET to report its fourth quarter and full year financial results and provide an upd
